European Biotech Act Advances as Council Agrees Negotiating Mandate on GMM and Organ Processing Reforms
Key Insights
The Council of the EU agreed on its negotiating position for targeted amendments to health legislation aimed at boosting biotechnology innovation across the European Union.
Certain genetically modified microorganisms meeting predefined safety standards would become eligible for an expedited regulatory procedure under the proposed reforms.
The Council introduced a 10-year limit on initial marketing consent for GMMs, with indefinite validity upon renewal, as an added safeguard.
The Council of the European Union (search) announced on June 16, 2026, that it has agreed on its negotiating position for targeted amendments to health legislation designed to strengthen biotechnology innovation across the EU. The proposed directive, drafted by the European Commission, would amend two existing directives to streamline rules governing the placement of certain genetically modified microorganisms (GMMs) on the market and to update organ processing regulations in light of scientific and clinical advances.
The measures form part of the broader European Biotech Act (search) and aim to accelerate the translation of biotechnology research into clinical and commercial applications by simplifying regulatory pathways for eligible products while maintaining established standards for safety, transparency, and public trust.
Expedited Pathway for Eligible GMMs
Under the Council's position, certain genetically modified microorganisms that meet predefined safety standards would become eligible for an expedited regulatory procedure. Notably, the Council proposed replacing the term "low risk genetically modified micro organisms" with "genetically modified micro organisms eligible for an expedited procedure," seeking to avoid any implication that products outside this category should automatically be considered high risk.
The Council further refined the draft legislation by aligning terminology with other relevant EU legislative acts, clarifying the respective competences of the European Commission and Member States, and reorganizing text elements and provisions to support consistent and effective implementation across the Union.
Consent Safeguards Introduced
A key modification introduced by the Council concerns the validity of marketing consent for GMMs. While the European Commission's original proposal would have granted indefinite validity to consent once issued, the Council introduced an added safeguard by limiting initial consent to a maximum of 10 years. Upon renewal, and unless certain exceptions apply, the consent would then be granted indefinitely.
Organ Processing Reforms Reflect Clinical Advances
The proposed reforms also address developments in organ transplantation, where scientific and clinical advances have extended the time that can safely elapse between organ procurement and transplantation, creating opportunities for innovative approaches to organ processing.
The Council clarified the distinction between autologous transplantation—where an organ is transplanted within the same individual—and transplantation between different people. Recognizing that autologous procedures frequently occur in emergency settings, the revised provisions aim to ensure that surgeons are not hindered by unnecessary regulatory requirements.
Additional provisions clarify that processing personal data in the context of organ transplantation may be considered in the public interest where necessary to support patient safety, maintain high healthcare standards, or facilitate cross-border data sharing to analyze transplant outcomes across a wider group of patients.
Next Steps
The proposal will now proceed to negotiations with the European Parliament once that institution has adopted its own position. The two institutions will then work toward agreement on the final legislative text, marking a significant step forward for the European Biotech Act (search) and the EU's broader ambitions in biotechnology innovation.